Source: Public company bulletin, meter intranet database Heng Rui Heavy in research products rushed out of the country | Pfizer's $ billion market meets rival

October 23 News October 22, Heng Rui Pharmaceutical issued a notice that the subsidiary of Rui Stone Biomedical Co., Ltd. in the United States time September 17, 2018 to the United States FDA submitted SHR0302 tablets clinical trial application and accepted, in accordance with the U.S. drug registration laws and regulations,

No "clinical trial" or "suspension of clinical trials" has been issued within 30th from the date of acceptance and may be approved for clinical trials, and the company will conduct clinical trials in the near future.

Table 1: Product conditions

(Source: Public company announcement) It is reported that Heng Rui Medicine in the SHR0302 is a small molecule JAK1 kinase selective inhibitor, intended for the treatment of ulcerative colitis.

SHR0302 Tablets of similar products have Pfizer developed by the law of Nepal.

Figure 1: Global sales of Pfizer in 2012-2017 (Million USD)

(Source: Meter Intranet Sales database of multinational listed companies) Founded in November 2012 in the United States, the first batch was approved for rheumatoid arthritis treatment and was approved for ulcerative colitis in May 2018, the only JAK kinase inhibitor currently approved for the treatment of ulcerative colitis, the Drug

It was approved for listing in China in March 2017.

In 2017, Pfizer's global sales volume exceeded $1.3 billion, according to data from the sales database of multinational listed companies in the M intranet. Hang Rui Medicine said that according to the United States Drug registration The relevant laws Regulations

requirements, the drug in the clinical trial qualification, still need to carry out clinical trials and approved by the U.S. FDA review and approval before the production of the listing, as of now the product project has been put into research and development costs of about 38.41 million yuan.